Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
D.A. Loblaw(American Society of Clinical Oncology), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Charles L. Bennett(University of South Carolina), James L. Wade(American Society of Clinical Oncology), Stewart A. Sharp(American Society of Clinical Oncology), Katherine S. Virgo(Emory University), Mark R. Somerfield(American Society of Clinical Oncology), Thomas J. Smith(Sidney Kimmel Cancer Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Richard Middleton(American Society of Clinical Oncology), David S. Mendelson(American Society of Clinical Oncology), James A. Talcott(ImmunityBio (United States)), Edgar Ben‐Josef(American Society of Clinical Oncology), Robert K. Nam(Sunnybrook Health Science Centre), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School)
Cited by 556
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k